UPDATED: PhII flop clouds future of Amgen, Cytokinetics heart failure drug FierceBiotech Cytokinetics shares ($CYTK) took a dive in early trading today after its partner Amgen ($AMGN) reported that an IV formulation of their heart failure drug omecamtiv mecarbil failed a key Phase IIb trial, just weeks after Amgen paid $25 million to ... Amgen, Cytokinetics Announce Disappointing Phase 2 Data For Heart Failure ... Cytokinetics skids on heart failure drug data ATOMIC-AHF: Cautious optimism for potential inotrope replacement in acute HF |
